Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

20041,347 citationsJournal Articlegreen Open Access

Authors

Henry G. Bone

David Hosking · Nottingham City Hospital

Jean‐Pierre Devogelaer · UCLouvain

Joseph Tucci

Ronald Emkey

Richard P. Tonino

Jose Adolfo Rodriguez-Portales · Pontificia Universidad Católica de Chile

Robert W. Downs · Virginia Commonwealth University

Jayanti Gupta

Abstract

The therapeutic effects of alendronate were sustained, and the drug was well tolerated over a 10-year period. The discontinuation of alendronate resulted in the gradual loss of its effects.

Topics & Keywords

Bone health and osteoporosis research Bone health and treatments Bone Metabolism and Diseases

UN Sustainable Development Goals

Gender equality

Publication Details

Published in: New England Journal of Medicine

Volume 350, Issue 12, pp. 1189-1199

DOI: 10.1056/nejmoa030897

Field-Weighted Citation Impact: 92.95